The global Genomics Personalized Health market accounted for USD 4,789.2 Million in 2020 and is expected to reach USD 6,649.2 Million by 2028, growing at a CAGR of 4.4% from 2021 to 2028.
The global Genomics Personalized Health market accounted for USD 4,789.2 Million in 2020 and is expected to reach USD 6,649.2 Million by 2028, growing at a CAGR of 4.4% from 2021 to 2028.
Genomics personalized health is an evolving field in which physicians use diagnostic tests to identify specific biological markers, often genetic, that help determine which medical treatments and procedures will work best for each patient. Personalized health care has the capacity to detect the onset of disease at its earliest stages, pre-empt the progression of disease, and, at the same time, increase the efficiency of the health care system by improving quality, accessibility, and affordability.
The dominance of the country is primarily based on huge presence of biopharmaceutical companies, government initiatives and supporting regulations, large number of research institute engaged in the study of personalized medicine, and strong presence of healthcare infrastructure that includes oncology clinics and diagnostic center equipped with advanced genomics technologies.
COVID pandemic has hampered almost all the sectors around the globe. However, it did not succeed in hampering the cancer and infectious disease care. It has been observed that the number of outpatients, the frequency of outpatient visits of doctors, the number of patients in wards and the number of surgery operations decreased by 80.3%, 50.0%, 70.6%, and 75.0% in the first two months of pandemic. This was majorly witnessed due to fear of catching infection, strict lockdown, unavailability of public transport, and ban on intercity travel, among others. In line with this, all hospitals have developed detailed guidelines for protecting potentially vulnerable cancer patients under different conditions and have rearranged non-urgent consultations to minimize a given cancer patient’s exposure to any health care setting.
Governments around the globe, especially in the developed countries, are taking extra efforts to increase affordability of healthcare to their citizen. In line with this, they are taking favorable steps to improve the market scenario. For instance, the US government has introduced a Health Information technology for Economic and Clinical Health (HITECH) Act, included as part of the American Recovery and Reinvestment Act of 2009 (ARRA), formalized the Office of the National Coordinator for Health Information Technology and established a funding stream for infrastructure and incentive payments to providers who adopt and use health IT in a meaningful way.
Despite rapid scientific and technological advancement, the health care system has been relatively slow to integrate personalized medicine into clinical practice. As per our findings, only 40% of the consumers are aware about the genomics personalized health. Out of which, hardly, 10% recommended or discussed the genomics personalized medicine with them. In addition to this, most of the health care organizations do not have formalized plans to leverage advances in genomics and data analytics to personalize patient care, and are unprepared to implement personalized medicine programs
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Technology Segment Analysis Preview
NGS Platforms segment held a share of around 59.50 % in 2020. This is attributable to the genome personalized medicine; they are used for molecular profiling in order to discover biomarker or targeted novel drug target. Transcriptome sequencing has been carried out to profile mRNA expression analysis and detect non-coding RNAs, such as miRNA, siRNA, piRNA, and lncRNA, which may be potential biomarkers. Additionally, epigenomic sequencing, such as ChIP-sequencing, ribosome profiling, and bisulfite sequencing, has merged as a powerful tool for drug development and clinical practice.
Oncology Testing segment held a share of around 41.38 % in 2020. This is attributable with the increasing prevalence of cancers, the market is experiencing robust demand for advanced treatment methods for improved outcome. This has further added fuel to the genomics of personalized therapy or medicine. With each passing year, a greater number of market players are trying to enter the area of personalized medicine for cancer treatment. Today, various research institutes, pharma companies, and diagnostics laboratories are making use of genomics for developing and identifying targeted personalized medicine. Moreover, it helps in understanding the pharmacogenomics of the cancer.
The North America region held a share of 38.31% in 2020. This is attributable to the presence of top companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, among others. Moreover, the increasing usage of automated solutions in logistics sector is expected to generate huge demand for the market in this region.
Europe region is projected to grow at a CAGR of 15.4% over the forecast period. The genomics personalized health market and the region is further expected to continue holding its dominance over the forecast period. This is majorly attributed to well-established healthcare industry, sophisticated healthcare as well as medical infrastructure, high healthcare spending, active presence of key industry players, and large number of players who have strategic pipeline in regard to the gene therapy and genomics technologies. Additionally, availability of research grants and funding is further supporting the related developments in genomics personalization of health and creating space for revenue opportunities.
Key Market Players & Competitive Landscape
Some key players in Genomics Personalized Health market are illumine, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Roche, Lonza Group, among others.
QIAGEN has launched the novel QIAseq Targeted Methyl panels, the first and only NGS-based products for targeted methylation analysis with the increased analytical sensitivity and sequence-targeting capabilities of the company’s proprietary Single Primer Extension technology
Thermo Fisher's growth strategy includes significant investment in and expenditures for product development. It sells its products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Its competitors may adapt more quickly to new technologies and changes in customers' requirements than it can. Without the timely introduction of new products, services and enhancements, products and services will likely become technologically obsolete over time, in which case revenue and operating results would suffer.
By Technology
By Test Type
By End-User
By Region
List of Figures
FIG NO. 1. Market Attractiveness Analysis, By Technology
FIG NO. 2. Market Attractiveness Analysis, By Test Type
FIG NO. 3. Market Attractiveness Analysis, By Regions
FIG NO. 4. Global Genomics Personalized Health Market Revenue, 2016 – 2028 (USD Million)
FIG NO. 5. Market Revenue Share, By Technology, 2020 & 2028
FIG NO. 6. Global Genomics Personalized Health Market for NGS platforms, Revenue (USD Million) 2016 – 2028
FIG NO. 7. Global Genomics Personalized Health Market for RT-PCR, Revenue (USD Million) 2016 – 2028
FIG NO. 8. Global Genomics Personalized Health Market for Microarray, Revenue (USD Million) 2016 – 2028
FIG NO. 9. Global Genomics Personalized Health Market for Genetic Analyzers, Revenue (USD Million) 2016 – 2028
FIG NO. 10. Market Revenue Share, By Test Type, 2020 & 2028
FIG NO. 11. Global Genomics Personalized Health Market for Oncology Testing, Revenue (USD Million) 2016 – 2028
FIG NO. 12. Global Genomics Personalized Health Market for Infectious Disease Testing, Revenue (USD Million) 2016 – 2028
FIG NO. 13. Global Genomics Personalized Health Market for Genetic Disease Testing, Revenue (USD Million) 2016 – 2028
FIG NO. 14. Global Genomics Personalized Health Market for Autoimmune Disease Testing, Revenue (USD Million) 2016 – 2028
FIG NO. 15. Global Genomics Personalized Health Market for Others, Revenue (USD Million) 2016 – 2028
FIG NO. 16. Market Revenue Share, By End User, 2020 & 2028
FIG NO. 17. Global Genomics Personalized Health Market for Research and Diagnostic Centers, Revenue (USD Million) 2016 – 2028
FIG NO. 18. Global Genomics Personalized Health Market for Academics, Revenue (USD Million) 2016 – 2028
FIG NO. 19. Global Genomics Personalized Health Market for Others, Revenue (USD Million) 2016 – 2028
FIG NO. 20. Global Genomics Personalized Health Market Revenue Share, By Region, 2020 & 2028
FIG NO. 21. North America Genomics Personalized Health Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 22. Company Share Analysis, 2019
FIG NO. 23. Research Methodology – Detailed View
FIG NO. 24. Research Methodology
List of Tables
TABLE NO. 1. Global Genomics Personalized Health Market: Snapshot
TABLE NO. 2. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 3. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 4. Global Genomics Personalized Health Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 5. North America Genomics Personalized Health Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 6. North America Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 7. North America Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 8. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 9. U.S. Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 10. U.S. Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 11. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 12. Canada Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 13. Canada Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 14. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 15. Europe Genomics Personalized Health Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 16. Europe Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 17. Europe Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 18. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 19. Germany Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 20. Germany Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 21. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 22. France Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 23. France Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 24. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 25. U.K Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 26. U.K Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 27. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 28. Italy Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 29. Italy Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 30. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 31. Spain Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 32. Spain Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 33. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 34. Rest of Europe Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 35. Rest of Europe Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 36. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 37. Asia Pacific Genomics Personalized Health Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 38. Asia Pacific Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 39. Asia Pacific Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 40. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 41. China Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 42. China Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 43. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 44. India Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 45. India Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 46. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 47. Japan Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 48. Japan Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 49. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 50. Korea Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 51. Korea Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 52. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 53. Southeast Asia Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 54. Southeast Asia Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 55. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 56. Rest of Asia Pacific Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 57. Rest of Asia Pacific Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 58. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 59. Latin America Genomics Personalized Health Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 60. Latin America Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 61. Latin America Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 62. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 63. Brazil Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 64. Brazil Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 65. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 66. Argentina Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 67. Argentina Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 68. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 69. Rest of Latin America Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 70. Rest of Latin America Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 71. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 72. MEA Genomics Personalized Health Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 73. MEA Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 74. MEA Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 75. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 76. GCC Countries Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 77. GCC Countries Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 78. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 79. South Africa Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 80. South Africa Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 81. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 82. Rest of MEA Genomics Personalized Health Market Revenue, By Technology, 2016 – 2028 (USD Million)
TABLE NO. 83. Rest of MEA Genomics Personalized Health Market Revenue, By Test Type, 2016 – 2028 (USD Million)
TABLE NO. 84. Genomics Personalized Health Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 85. Drivers for the Genomics Personalized Health Market: Impact Analysis
TABLE NO. 86. Global Genomics Personalized Health Market, Company Market Revenue, 2019 (USD Million)
The global Genomics Personalized Health Market was valued at USD 11,229 Million in 2020.
The global Genomics Personalized Health Market is expected to reach USD 34,009 Million by 2028, growing at a CAGR of 14.6% between 2021 to 2028.
Some of the key factors driving the global genomics personalized health market growth are favorable government policies and increasing number of genomic personalized medicine.
North America region held a substantial share of the 38.31% in 2020. This is attributable to the presence of major players such as Bio-Rad Laboratories, Roche, Lonza Group, among others.
Some of the major companies operating in the Genomics Personalized Health Market are illumine, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Roche, Lonza Group, among others.
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed